| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/08/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 08/09/2022 | 33.74% | Raymond James | $208 → $190 | Maintains | Outperform |
| 08/09/2022 | 58.37% | Keybanc | $230 → $225 | Maintains | Overweight |
| 08/08/2022 | 46.41% | Raymond James | $235 → $208 | Maintains | Outperform |
| 08/03/2022 | 61.89% | Keybanc | $265 → $230 | Maintains | Overweight |
| 05/10/2022 | 86.53% | Keybanc | $280 → $265 | Maintains | Overweight |
| 05/10/2022 | 65.41% | Raymond James | $265 → $235 | Maintains | Outperform |
| 02/28/2022 | 86.53% | Raymond James | $286 → $265 | Maintains | Outperform |
| 10/22/2021 | 97.09% | Keybanc | $302 → $280 | Maintains | Overweight |
| 09/09/2021 | 101.31% | Raymond James | $220 → $286 | Maintains | Outperform |
| 09/09/2021 | 112.57% | Keybanc | $225 → $302 | Maintains | Overweight |
| 08/06/2021 | 58.37% | Keybanc | $236 → $225 | Maintains | Overweight |
| 08/05/2021 | 54.85% | Raymond James | $245 → $220 | Maintains | Outperform |
| 02/26/2021 | 72.45% | Raymond James | $235 → $245 | Maintains | Outperform |
| 02/11/2021 | 65.41% | Raymond James | $210 → $235 | Maintains | Outperform |
| 01/08/2021 | 66.12% | Keybanc | $222 → $236 | Maintains | Overweight |
| 11/06/2020 | 56.26% | Keybanc | $218 → $222 | Maintains | Overweight |
| 09/02/2020 | 53.45% | Keybanc | $199 → $218 | Maintains | Overweight |
| 08/11/2020 | 47.81% | Raymond James | $228 → $210 | Maintains | Outperform |
| 05/13/2020 | 40.07% | Keybanc | $206 → $199 | Maintains | Overweight |
| 05/08/2020 | 60.48% | Raymond James | $215 → $228 | Maintains | Outperform |
| 03/18/2020 | 45% | Keybanc | → $206 | Upgrades | Sector Weight → Overweight |
| 02/28/2020 | 51.33% | Raymond James | $203 → $215 | Maintains | Outperform |
| 08/08/2019 | — | Raymond James | Downgrades | Strong Buy → Outperform | |
| 03/01/2019 | 111.16% | Raymond James | $315 → $300 | Maintains | Strong Buy |
ICU Medical Questions & Answers
The latest price target for ICU Medical (NASDAQ: ICUI) was reported by Raymond James on November 8, 2022. The analyst firm set a price target for $0.00 expecting ICUI to fall to within 12 months (a possible -100.00% downside). 8 analyst firms have reported ratings in the last year.
The latest analyst rating for ICU Medical (NASDAQ: ICUI) was provided by Raymond James, and ICU Medical downgraded their market perform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ICU Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ICU Medical was filed on November 8, 2022 so you should expect the next rating to be made available sometime around November 8, 2023.
While ratings are subjective and will change, the latest ICU Medical (ICUI) rating was a downgraded with a price target of $0.00 to $0.00. The current price ICU Medical (ICUI) is trading at is $142.07, which is out of the analyst's predicted range.